Bimoclomol improves early electrophysiological signs of retinopathy in diabetic rats.
A silent process involving both neural and vascular structures in diabetic retina persists for several years before clinically detectable retinopathy. Recordings of the electroretinogram (ERG) and visual evoked potential (VEP) provide early warning of abnormalities in the visual pathway of diabetic patients and animal models. Treatment of streptozotocin-diabetic rats for 1 or 2 months with the heat-shock protein coinducer bimoclomol, a drug ameliorating experimental neuropathy, prevented and corrected the abnormal increase in latency and reduction of amplitude of ERG and VEP waves both in acute and chronic experiments. Improvements may be explained by cytoprotective effect of bimoclomol on retinal glia and/or neurons against diabetes-related ischemic cell damages. These findings suggest that bimoclomol may have future therapeutic use in diabetic retinopathy.
Biorex Research and Development Company, Veszprém, Hungary.
K
K
Bíró
J
J
Pálhalmi
A J
AJ
Tóth
T
T
Kukorelli
G
G
Juhász
D000758:Anesthesia; D000818:Animals; D003921:Diabetes Mellitus, Experimental / Q000503:physiopathology; D003930:Diabetic Retinopathy / Q000188:drug therapy* / Q000503:physiopathology*; D004594:Electrophysiology; D004596:Electroretinography; D005074:Evoked Potentials, Visual / Q000187:drug effects / Q000502:physiology; D007094:Imides / Q000627:therapeutic use*; D008297:Male; D010775:Photic Stimulation; D011725:Pyridines / Q000627:therapeutic use*; D051381:Rats; D011919:Rats, Inbred Strains; D012160:Retina / Q000503:physiopathology; D014793:Visual Cortex / Q000503:physiopathology
D007094:Imides; D011725:Pyridines; C108730:bimoclomol